Helix BioPharma makes two appointments
Jack Kay as chairman and Professor Kazimierz Roszkowski-Sliz as European Medical Director
Helix has also hired Professor Kazimierz Roszkowski-Śliż as European Medical Director, to provide critical oversight and direction for Helix’s upcoming European L-DOS47 clinical programme.
Kay has been a director of Helix since 2005. He has worked in the pharmaceutical industry for more than 45 years, and since 1995 has been president of Apotex.
Professor Roszkowski-Śliż is an expert in the field of lung disease and lung cancers, and is a director at the National Tuberculosis and Lung Diseases Research Institute in Warsaw, Poland, where he is also head of the clinical department.
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
The path to commercial allogeneic iPSC therapies
The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Research & Development
The IND advantage: why early derisking is a strategic imperative for complex biologics
As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Research & Development
Stipple Bio enters into multi-target license agreement with Lonza to advance precision oncology ADC therapies
Stipple Bio’s Pointillist Platform identifies tumour-specific cell surface epitopes that, when combined with Lonza’s clinically validated ADC platform, may enable first-in-class and best-in-class ADC oncology medicines such as STP-100
Research & Development
Lonza advances integrated DNA‑to‑IND programmes with acceleration, derisking and innovation
New GS Ori‑Go vector technology supports titers higher than 11 g/L and reliable bulk pool stability, enabling more predictable material generation and shortened cell line development timelines